| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA989: Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B |
|
Medicine details |
|
| Medicine name | etranacogene dezaparvovec (Hemgenix®) |
| Formulation | Intravenous infusion |
| Reference number | 3953 |
| Indication | Prevention of bleeding episodes in adults (18 years & over) with moderate-to-severe Haemophilia B without inhibitors |
| Company | UniQure Biopharma BV |
| BNF chapter | Nutrition & blood |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 11/06/2024 |
| NICE guidance | TA989: Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B |